EX-10.2





 Exhibit 10.2 

RENEO PHARMACEUTICALS, INC. 

STOCK OPTION GRANT NOTICE 

(2014 EQUITY INCENTIVE PLAN) 

Reneo Pharmaceuticals, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby
grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein, in the Option Agreement, the Plan and the Notice of
Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option
Agreement. If there is any conflict between the terms herein and the Plan, the terms of the Plan will control. 
  

			
	 Optionholder:
	  	 
	 Date of Grant:
	  	 
	 Vesting Commencement Date:
	  	 
	 Number of Shares Subject to Option:
	  	 
	 Exercise Price (Per Share):
	  	 
	 Total Exercise Price:
	  	 
	 Expiration Date:
	  	 

  

									
	Type of Grant:	  	☐	  	Incentive Stock Option1	  	☐	  	Nonstatutory Stock Option
					
	Exercise Schedule:	  	☐	  	Same as Vesting Schedule	  	☐	  	Early Exercise Permitted
		
	Vesting Schedule:	  	 [1/4th of the shares vest one year after the Vesting Commencement Date; the
balance of the
 shares vest in a series of 36 successive equal monthly installments measured from the first

anniversary of the Vesting Commencement Date, subject to Optionholder’s Continuous

Service as of each such date.]

		
	Payment:	  	By one or a combination of the following items (described in the Option Agreement):
			
		  	☐	  	By cash, check, bank draft or money order payable to the Company
		  	☐	  	Pursuant to a Regulation T Program if the shares are publicly traded
		  	☐	  	By delivery of already-owned shares if the shares are publicly traded
		  	☐	  	By deferred payment
		  	☐	  	If and only to the extent this option is a Nonstatutory Stock Option, and subject to the
		  	Company’s consent at the time of exercise, by a “net exercise” arrangement

  

	1 	 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. 














 Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees
to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan.
By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the
Company or another third party designated by the Company. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and
the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options or other compensatory stock awards previously
granted and delivered to Optionholder, and (ii) the following agreements only. 
  

			
	 OTHER AGREEMENTS: 
	  	 
		  	 

  

									
	 RENEO PHARMACEUTICALS, INC.
	 		 	 OPTIONHOLDER:

					
	By:	 	   
	 	    	 	 	 	   

		 	Signature	 		 		 	Signature
	Title:	 	 	 		 	Date:	 	 
	Date:	 	 	 		 		 	

 ATTACHMENTS: Option Agreement, 2014 Equity Incentive Plan and Notice of Exercise 












 ATTACHMENT I 

OPTION AGREEMENT 












 RENEO PHARMACEUTICALS, INC. 

2014 EQUITY INCENTIVE PLAN 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK
OPTION) 
 Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement,
Reneo Pharmaceuticals, Inc. (the “Company”) has granted you an option under its 2014 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock
indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict
between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the
Plan. 
 The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of
your Continuous Service. 
 2. NUMBER OF SHARES AND
EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. 

3. EXERCISE RESTRICTION FOR
NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six months of Continuous Service measured from the Date of Grant.

 4. EXERCISE PRIOR TO VESTING (“EARLY
EXERCISE”). If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your
option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided,
however, that: 
 (a) a partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the
earliest vesting installment of unvested shares of Common Stock; 
 (b) any shares of Common Stock so purchased from installments
that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

  
 1. 













 (c) you will enter into the Company’s form of Early Exercise Stock Purchase
Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and 
 (d) if your
option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are
exercisable for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will
be treated as Nonstatutory Stock Options. 
 5. METHOD OF PAYMENT. You must pay
the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice,
which may include one or more of the following: 
 (a) Provided that at the time of exercise the Common Stock is publicly traded,
pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to
pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise,” “same day sale,” or “sell to cover.” 

(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or
attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes,
in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by
delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net
exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise
price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not
be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding
obligations. 

  
 2. 













 (d) Pursuant to the following deferred payment alternative: 

(i) Not less than 100% of the aggregate exercise price, plus accrued interest, will be due four years from date of exercise or, at the
Company’s election, upon termination of your Continuous Service. 
 (ii) Interest will be compounded at least annually and will
be charged at the minimum rate of interest necessary to avoid (1) the treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement and
(2) the classification of your option as a liability for financial accounting purposes. 
 (iii) In order to elect the deferred
payment alternative, you must, as a part of your written notice of exercise, give notice of the election of this payment alternative and, in order to secure the payment of the deferred exercise price to the Company hereunder, if the Company so
requests, you must tender to the Company a promissory note and a pledge agreement covering the purchased shares of Common Stock, both in form and substance satisfactory to the Company, or such other or additional documentation as the Company may
request. 
 6. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

 7. SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless
the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if not registered, the Company has determined that such exercise and the issuance of the shares would be exempt from the registration
requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

8. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s
term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

(a) immediately upon the termination of your Continuous Service for Cause; 

(b) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death
(except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to
“Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; provided
further, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six months after the Date of Grant, and (iii) you have vested in a portion of your option at the
time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven months after 

  
 3. 













 
the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service, and (y) the Expiration Date; 

(c) 12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in
Section 8(d)) below; 
 (d) 18 months after your death if you die either during your Continuous Service or within three months
after your Continuous Service terminates for any reason other than Cause; 
 (e) the Expiration Date indicated in your Grant Notice;
or 
 (f) the day before the 10th anniversary of the Date of Grant. 

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or your
permanent and total disability, as defined in Section 22(e)(3) of the Code. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily
be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date
your employment with the Company or an Affiliate terminates. 
 9. EXERCISE. 

(a) You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable
withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require. 

(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into
an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares
of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon
exercise of your option. 

  
 4. 













 (d) By exercising your option, you agree to be bound by the provisions of, and
execute a counterpart signature to, (i) that certain Voting Agreement, dated as of December 22, 2017, as such agreement may be restated or amended from time to time (the “Voting Agreement”), by and among the Company
and each Key Holder and Investor party thereto (as such terms are defined in the Voting Agreement), and (ii) that certain Right of First Refusal and Co-Sale Agreement, dated as of December 22, 2017,
as such agreement may be restated or amended from time to time (the “Co-Sale Agreement”), by and among the Company and each Key Holder and Investor party thereto (as such terms are
defined in the Co-Sale Agreement), and to be deemed a “Key Holder” under the Voting Agreement and the Co-Sale Agreement for purposes thereof. Copies of the
Voting Agreement and Co-Sale Agreement are available for your inspection upon request. 
 (e)
By accepting your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to
any shares of Common Stock or other securities of the Company held by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or
the Company will request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation (the “Lock-Up Period”); provided,
however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such
other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this
Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

10. TRANSFERABILITY. Except as otherwise provided in this Section 10, your option is not transferable,
except under the terms of your will or by the laws of descent and distribution, and is exercisable during your life only by you. 

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your
option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements
required by the Company. 
 (b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized
designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement
or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to


  
 5. 













 
discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information
is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering
written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the
Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or
other consideration resulting from such exercise. 
 11. RIGHT OF FIRST
REFUSAL. Shares of Common Stock that you acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its
right. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation system. 

12. RIGHT OF REPURCHASE. To the extent provided in the Company’s bylaws in
effect at such time the Company elects to exercise its right, the Company will have the right to repurchase all or any part of the shares of Common Stock you acquire pursuant to the exercise of your option. 

13. OPTION NOT A SERVICE CONTRACT. Your option is not
an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your
employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the
Company or an Affiliate. 
 14. WITHHOLDING OBLIGATIONS. 

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
option. 
 (b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and
compliance with any applicable legal conditions or 

  
 6. 













 
restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair
Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for
financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless
you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the
determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date
of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. 

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. 
 15. TAX
CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not
make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from
Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral
of compensation associated with the option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the
Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service. 

16. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including
electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last address you
provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By
accepting this option, you consent to receive such documents by 

  
 7. 













 
electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party
designated by the Company. 
 17. GOVERNING PLAN DOCUMENT. Your option is subject
to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to
the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. 

18. EFFECT ON OTHER EMPLOYEE BENEFIT
PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the
Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans. 

19. VOTING RIGHTS. You will not have voting or any other rights as a
stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in
this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. 

20. SEVERABILITY. If all or any part of this Option Agreement or the Plan is
declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option
Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful
and valid. 
 21. MISCELLANEOUS. 

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all
covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns. 

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your option. 
 (c) You acknowledge and agree that you have reviewed your option in
its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. 

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental
agencies or national securities exchanges as may be required. 

  
 8. 













 (e) All obligations of the Company under the Plan and this Option Agreement will be binding
on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. 

*        *         * 

This Option Agreement will be deemed to be signed by you upon the signing by 

you of the Stock Option Grant Notice to which it is attached. 

  
 9. 













 ATTACHMENT II 

2014 EQUITY INCENTIVE PLAN 












 ATTACHMENT III 

NOTICE OF EXERCISE 












 NOTICE OF EXERCISE 

Reneo Pharmaceuticals, Inc. 
 12230 El Camino Real, Suite 230


					
	San Diego, California 92130	  		  	                Date
of Exercise:                    

 This constitutes notice to RENEO PHARMACEUTICALS, INC.
(the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below. 

 

									
	 Type of option (check one):
	  	 	Incentive ☐	 	 	 	Nonstatutory ☐	 
	 Stock option dated:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Number of Shares as to which option is exercised:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Certificates to be issued in name of:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Total exercise price:
	  	$	______________	 	 	$	______________	 
	 Cash payment delivered herewith:
	  	$	______________	 	 	$	______________	 

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and
(iii) if this exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant
of this option or within one year after such Shares are issued upon exercise of this option. 
 I hereby make the following certifications
and representations with respect to the number of Shares listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: 

I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of distributing or selling
said Shares, except as permitted under the Securities Act and any applicable state securities laws. 
 I further acknowledge that I will not
be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of 

  
 1. 













 
Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the Option shall have endorsed thereon
appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s articles of incorporation, bylaws and/or applicable securities laws. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten
registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred 180 days following the effective date of a registration statement of the Company filed under the Securities Act
(or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) (the
“Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such period. 
 I further agree, in connection with this exercise, (a) to automatically become a party
to, and be bound by and subject to the terms of (i) that certain Voting Agreement, dated as of December 22, 2017, as such agreement may be restated or amended from time to time (the “Voting Agreement”), by and among
the Company and each Key Holder and Investor party thereto (as such terms are defined in the Voting Agreement), and (ii) that certain Right of First Refusal and Co-Sale Agreement, dated as of
December 22, 2017, as such agreement may be restated or amended from time to time (the “Co-Sale Agreement”), by and among the Company and each Key Holder and Investor party thereto
(as such terms are defined in the Co-Sale Agreement) and (b) to execute any counterparts or similar agreements evidencing such agreements upon request of the Company and I hereby appoint any officer of
the Company as my attorney-in-fact to execute any such agreements. I agree to seek the consent of my spouse to the extent required by the Company to enforce the
foregoing. I acknowledge that the Company has made a copy of the Voting Agreement and Co-Sale Agreement available to me. 

 

	
	
	Very truly yours,
	
	
	Signature of Optionholder
	    
	Print Name of Optionholder



  
 2. 













 RENEO PHARMACEUTICALS, INC. 

Counterpart to 
 Voting
Agreement and 
 Co-Sale Agreement 

The undersigned hereby agrees to become a party to that certain Right of First Refusal and Co-Sale
Agreement (the “Co-Sale Agreement”), and that certain Voting Agreement (the “Voting Agreement” and together with the
Co-Sale Agreement, the “Shareholder Agreements”), in each case dated as of December 22, 2017, by and among Reneo Pharmaceuticals, Inc. and the parties named therein
respectively. Effective as of the date that this Counterpart is executed and delivered by the undersigned, the undersigned (a) is hereby made a party to the Voting Agreement as a “Key Holder” thereunder and agrees to be bound by and
subject to all of the terms and provisions of the Voting Agreement applicable to a Key Holder and (b) is hereby made a party to the Co-Sale Agreement as a “Key Holder” thereunder and agrees to
be bound by and subject to all of the terms and provisions of the Co-Sale Agreement applicable to a Key Holder. The undersigned agrees that this Counterpart may be attached to each of the Shareholder
Agreements as a counterpart signature page thereto. 
 The undersigned acknowledges receipt of a copy of each of the Shareholder Agreements.
The address and email address to which notices may be sent to the undersigned is as follows: 
  

			
	 	 	 
	 	 	 
	 	 	 
	Email:	 	 

  

			
	 	 	 
		
	Print Name:	 	 


 
			
		
	Date:	 	 



  
 3. 













 RENEO PHARMACEUTICALS, INC. 

STOCK OPTION GRANT NOTICE 

(UK SUB-PLAN TO 2014 EQUITY INCENTIVE PLAN) 

Reneo Pharmaceuticals, Inc. (the “Company”), pursuant to the UK Sub-Plan to its 2014 Equity
Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth
herein, in the Option Agreement, the Plan, the UK Sub-Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined
herein but defined in the Plan, the UK Sub-Plan or the Option Agreement will have the same definitions as in the Plan, the UK Sub-Plan or the Option Agreement. If there
is any conflict between the terms herein and the Plan and the UK Sub-Plan, the terms of the UK Sub-Plan will control. 

 

			
	 Optionholder:
	  	 
	 Date of Grant:
	  	 
	 Vesting Commencement Date:
	  	 
	 Number of Shares Subject to Option:
	  	 
	 Exercise Price (Per Share):
	  	 
	 Total Exercise Price:
	  	 
	 Expiration Date:
	  	 

  

			
	Type of Grant:	  	☐    EMI Option under Schedule 5 to the Income             ☐    Nonstatutory Stock Option Tax (Earnings and
Pensions) Act 2003
		
	Exercise Schedule:	  	☐    Same as Vesting Schedule             ☐    Early Exercise Permitted
		
	Vesting Schedule:	  	1/4th of the shares vest one year after the Vesting Commencement Date and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date,
subject to Optionee’s Continuous Service (as defined in the Plan) as of each such vesting date.
		
	Payment:	  	☐    By cash, cheque, bank draft or money order payable to the Company













 Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees
to, this Stock Option Grant Notice, the Option Agreement, the Plan and the UK Sub-Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified,
amended or revised except as provided in the Plan and the UK Sub-Plan. By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the UK Sub-Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Optionholder further acknowledges
that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, the Plan and the UK Sub-Plan set forth the entire understanding between Optionholder and the Company regarding the
acquisition of stock in the Company and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options or other compensatory stock awards previously granted and delivered to
Optionholder, and (ii) the following agreements only. 
  

			
	 OTHER AGREEMENTS:
	  	 
		  	 

 The undersigned Optionholder declares that he or she works for the Company whose shares of Common Stock are the subject of
this EMI Option or for a subsidiary of the Company for at least 25 hours per week. 
  

							
	 RENEO PHARMACEUTICALS, INC.
	 		 	OPTIONHOLDER:
				
	By:	 	   
	 		 	   

		 	Signature	 		 	Signature
	Title:	 	 	 		 	Date:
                                         
                                         
              
	Date:	 	 	 		 	

 ATTACHMENTS: Option Agreement, 2014 Equity Incentive Plan, the UK Sub-Plan and Notice of Exercise 












 ATTACHMENT I 

OPTION AGREEMENT 












 RENEO PHARMACEUTICALS, INC. 

UK SUB-PLAN TO 2014 EQUITY INCENTIVE PLAN 

OPTION AGREEMENT 

(EMI OR NONSTATUTORY STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Reneo Pharmaceuticals, Inc.
(the “Company”) has granted you an option under the UK Sub-Plan to its 2014 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the
Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of
Grant”). If there is any conflict between the terms in this Option Agreement and the Plan and the UK Sub-Plan, the terms of the UK Sub-Plan will control.
Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan and the UK Sub-Plan will have the same definitions as in the Plan and the UK Sub-Plan. 
 Your option is an EMI Option granted in accordance with the provision of Schedule 5 to the
Income Tax (Earnings and Pensions) Act 2003. The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1.    VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon
the termination of your Continuous Service. 
 2.    NUMBER OF
SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization
Adjustments. 
 3.    METHOD OF PAYMENT. You must pay the
full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by cheque, bank draft or money order payable to the Company If this option is a Nonstatutory Stock Option, subject to the consent of the
Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market
Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no
longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and
(iii) are withheld to satisfy your tax withholding obligations. 
 4.    WHOLE
SHARES. You may exercise your option only for whole shares of Common Stock. 

5.    SECURITIES LAW COMPLIANCE. In no event may you exercise
your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if not registered, the Company has determined that such exercise and the issuance of the shares would be exempt from the
registration requirements of the Securities Act. The exercise of 

  
 1. 













 
your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be
in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

6. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s
term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

(a) immediately upon the termination of your Continuous Service for Cause; 

(b) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death
(except as otherwise provided in Section 7(d) below); provided, however, that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to
“Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; 

(c) 12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in
Section 8(d)) below; 
 (d) 12 months after your death if you die either during your Continuous Service or within three months
after your Continuous Service terminates for any reason other than Cause; 
 (e) the Expiration Date indicated in your Grant Notice;
or 
 (f) the day before the 10th anniversary of the Date of Grant. 

Please note that the tax treatment of an EMI Option may change if the EMI Option is exercised more than 90 days following the date of
termination of your Continuous Service. 
 7. EXERCISE. 

(a) You may exercise the vested portion of your option during its term by (i) delivering a Notice of Exercise (in a form designated
by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or
such other person as the Company may designate, together with such additional documents as the Company may then require. 
 (b) By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising
by reason of the exercise of your option. 
 (c) By exercising your option, you agree to be bound by the provisions of, and execute a
counterpart signature to, (i) that certain Voting Agreement, dated as of December 22, 

  
 2. 













 
2017, as such agreement may be restated or amended from time to time (the “Voting Agreement”), by and among the Company and each Key Holder and Investor party thereto (as
such terms are defined in the Voting Agreement), and (ii) that certain Right of First Refusal and Co-Sale Agreement, dated as of December 22, 2017, as such agreement may be restated or amended from
time to time (the “Co-Sale Agreement”), by and among the Company and each Key Holder and Investor party thereto (as such terms are defined in the
Co-Sale Agreement), and to be deemed a “Key Holder” under the Voting Agreement and the Co-Sale Agreement for purposes thereof. Copies of the Voting Agreement
and Co-Sale Agreement are available for your inspection upon request. 
 (d) By accepting
your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of
Common Stock or other securities of the Company held by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company
will request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation (the “Lock-Up Period”); provided, however, that
nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as
may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 7(d). The underwriters of
the Company’s stock are intended third party beneficiaries of this Section 7(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

8. TRANSFERABILITY. Your option is not transferable, except on death to your personal representative, and is
exercisable during your life only by you. 
 9. RIGHT OF FIRST
REFUSAL. Shares of Common Stock that you acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its
right. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation system. 

10. RIGHT OF REPURCHASE. To the extent provided in the Company’s bylaws in
effect at such time the Company elects to exercise its right, the Company will have the right to repurchase all or any part of the shares of Common Stock you acquire pursuant to the exercise of your option. 

11. OPTION NOT A SERVICE CONTRACT. 

(a) Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any
obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your 

  
 3. 













 
employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship
that you might have as a Director or Consultant for the Company or an Affiliate. 
 (b) The grant of options under the Plan is made
at the discretion of the Company and the Plan may be suspended or terminated by the Company at any time. The grant of an option in one year or at one time does not in any way entitle you to an option grant in the future. The Plan is wholly
discretionary and is not to be considered part of your normal or expected compensation subject to severance, resignation, redundancy or similar compensation. The value of your option is an extraordinary item of compensation which is outside the
scope of your employment contract (if any). 
 (c) You hereby waive all and any rights to compensation or damages in consequence of
your termination of employment for any reason whatsoever (whether lawful or unlawful and including, without prejudice to the generality of the foregoing, in circumstances giving rise to a claim for wrongful dismissal) insofar as those rights arise
or may arise from you ceasing to have rights under or being entitled to exercise your option as a result of such termination, or from the loss or diminution in value of such rights or entitlements. 

12. WITHHOLDING OBLIGATIONS. 

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an
Affiliate, if any, which arise in connection with the exercise of your option. 
 (b) If this option is a Nonstatutory Stock Option,
then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your
option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to
avoid classification of your option as a liability for financial accounting purposes). 
 (c) As a condition of the exercise of your
option, you unconditionally and irrevocably agree: 
 (i) to place the Company in funds and indemnify the Company in respect of
(1) all liability to UK income tax which the Company is liable to account for on your behalf directly to HM Revenue & Customs; (2) all liability to national insurance contributions which the Company is liable to account for on
your behalf to HM Revenue & Customs (including secondary class 1 (employer’s) national insurance contributions for which you are liable and hereby agree to pay); and (3) to the extent legally permitted, all liability to national
insurance contributions for which the Company is liable but have been formally transferred to you, which in all cases arise as a consequence of or in connection with the vesting or exercise of your option, your entering into of any tax election as
detailed below or your ownership of Common Stock by virtue of such 

  
 4. 













 
exercise including, without limitation, in respect of any liability arising under or in connection with Part 7 or Part 7A of the Income Tax (Earnings and Pensions) Act 2003
(“ITEPA”) (the “UK Tax Liability”); or 
 (ii) to permit the Company to sell at the best price
which it can reasonably obtain such number of shares of Common Stock allocated or allotted to you following exercise as will provide the Company with an amount equal to the UK Tax Liability; and to permit the Company to withhold an amount not
exceeding the UK Tax Liability from any payment made to you (including, but not limited to, salary); and 
 (iii) if so required by
the Company, and to the extent permitted by law, to enter into a joint election or other arrangements under which the liability for all or part of such employer’s national insurance contributions liability is transferred to you; and 

(iv) if so required by the Company, to enter into a joint election within Section 431 of the Income Tax (Earnings and Pensions)
Act 2003 (“ITEPA”) in respect of computing any tax charge on the acquisition of “restricted securities” (as defined in Section 423 and 424 of ITEPA); and 

(v) to sign, promptly, all documents, required by the Company to effect the terms of this provision, and references in this provision
to “the Company” shall, if applicable, be construed as also referring to any Affiliate. 
 (d) You may not exercise your
option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to
issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. 

13. TAX CONSEQUENCES. You hereby agree that the Company does not have
a duty to design or administer the Plan or the UK Sub-Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its
Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. 
 14.
DATA PROTECTION. By participating in the Plan, you acknowledge the collection, processing, transmission and storage in any form whatsoever by the Company or any Affiliate of any data of a
professional or personal nature which is necessary for the purpose of introducing and sustaining the Plan. This may include providing information to trustees of an employee benefit trust, or to registrars, or brokers, or third party administrators
of the Plan, or to future purchasers of the Company or the business in which you work. By participating in the Plan you also consent to the transfer of personal data to countries or territories outside the European Economic Area. 

15. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including
electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United Kingdom mail, postage prepaid, addressed to you at the last address you
provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in 

  
 5. 













 
the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by
electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

16. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the
Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any
conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. 
 17.
EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries,
or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or
terminate any of the Company’s or any Affiliate’s employee benefit plans. 
 18. VOTING
RIGHTS. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such
issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary
relationship between you and the Company or any other person. 
 19. SEVERABILITY.
If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared
to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section
to the fullest extent possible while remaining lawful and valid. 
 20. MISCELLANEOUS. 

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all
covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns. 

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your option. 
 (c) You acknowledge and agree that you have reviewed your option in
its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. 

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental
agencies or national securities exchanges as may be required. 

  
 6. 













 (e) All obligations of the Company under the Plan and this Option Agreement will be binding
on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. 

*        *         * 

This Option Agreement will be deemed to be signed by you upon the signing by 

you of the Stock Option Grant Notice to which it is attached. 

  
 7. 













 ATTACHMENT II 

2014 EQUITY INCENTIVE PLAN 












 ATTACHMENT III 

NOTICE OF EXERCISE 












 NOTICE OF EXERCISE 

Reneo Pharmaceuticals, Inc. 
 12230 El Camino Real, Suite 230 


					
	San Diego, California 92130	  		  	                Date of Exercise:                 
   

 This constitutes notice to RENEO PHARMACEUTICALS, INC.
(the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below. 

 

									
	 Type of option (check one):
	  	 	EMI ☐	 	 	 	Nonstatutory ☐	 
	 Stock option dated:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Number of Shares asto which option is exercised:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Certificates to be issued in name of:
	  				 			
		  	  
	  
	 	 	  
	  
	 
	 Total exercise price:
	  	$	______________	 	 	$	______________	 
	 Cash payment delivered herewith:
	  	$	______________	 	 	$	______________	 

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan and the UK Sub-Plan including, but not limited to, a joint election under Section 431 of the Income Tax (Earnings and Pensions) Act 2003
and a joint election for the transfer of employer’s national insurance contributions, and (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of
this option. 
 I hereby make the following certifications and representations with respect to the number of Shares listed above, which are
being acquired by me for my own account upon exercise of the option as set forth above: 
 I acknowledge that the Shares have not been
registered under the Securities Act of 1933, as amended (the “Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and
represent to the Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 

I further acknowledge that I will not be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded
(i.e., subject to the reporting requirements of 

  
 1. 













 
Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the Option shall have endorsed thereon
appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s articles of incorporation, bylaws and/or applicable securities laws. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten
registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred 180 days following the effective date of a registration statement of the Company filed under the Securities Act
(or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) (the
“Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such period. 
 I further agree, in connection with this exercise, (a) to automatically become a party
to, and be bound by and subject to the terms of (i) that certain Voting Agreement, dated as of December 22, 2017, as such agreement may be restated or amended from time to time (the “Voting Agreement”), by and among
the Company and each Key Holder and Investor party thereto (as such terms are defined in the Voting Agreement), and (ii) that certain Right of First Refusal and Co-Sale Agreement, dated as of
December 22, 2017, as such agreement may be restated or amended from time to time (the “Co-Sale Agreement”), by and among the Company and each Key Holder and Investor party thereto
(as such terms are defined in the Co-Sale Agreement) and (b) to execute any counterparts or similar agreements evidencing such agreements upon request of the Company and I hereby appoint any officer of
the Company as my attorney-in-fact to execute any such agreements. I agree to seek the consent of my spouse to the extent required by the Company to enforce the
foregoing. I acknowledge that the Company has made a copy of the Voting Agreement and Co-Sale Agreement available to me. 

 

	
	Very truly yours,
	
	
	Signature of Optionholder
	   

	Print Name of Optionholder



  
 2. 













 RENEO PHARMACEUTICALS, INC. 

Counterpart to 
 Voting
Agreement and 
 Co-Sale Agreement 

The undersigned hereby agrees to become a party to that certain Right of First Refusal and Co-Sale
Agreement (the “Co-Sale Agreement”), and that certain Voting Agreement (the “Voting Agreement” and together with the
Co-Sale Agreement, the “Shareholder Agreements”), in each case dated as of December 22, 2017, by and among Reneo Pharmaceuticals, Inc. and the parties named therein
respectively. Effective as of the date that this Counterpart is executed and delivered by the undersigned, the undersigned (a) is hereby made a party to the Voting Agreement as a “Key Holder” thereunder and agrees to be bound by and
subject to all of the terms and provisions of the Voting Agreement applicable to a Key Holder and (b) is hereby made a party to the Co-Sale Agreement as a “Key Holder” thereunder and agrees to
be bound by and subject to all of the terms and provisions of the Co-Sale Agreement applicable to a Key Holder. The undersigned agrees that this Counterpart may be attached to each of the Shareholder
Agreements as a counterpart signature page thereto. 
 The undersigned acknowledges receipt of a copy of each of the Shareholder Agreements.
The address and email address to which notices may be sent to the undersigned is as follows: 
  

			
	 	 	 
	 	 	 
	Email:	 	 

  

			
	 	 	 
	  
 Print Name:
	 	 


 
			
	Date:	 	 



  
 3.